Manfredi Rizzo to Hypoglycemic Agents
This is a "connection" page, showing publications Manfredi Rizzo has written about Hypoglycemic Agents.
Connection Strength
1.301
-
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021 Nov; 20(11):1309-1315.
Score: 0.362
-
Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study. Diabetes Res Clin Pract. 2019 Mar; 149:163-169.
Score: 0.304
-
Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights. J Cardiovasc Pharmacol Ther. 2020 11; 25(6):494-496.
Score: 0.084
-
Advances in pharmacological treatment of type 1 diabetes during pregnancy. Expert Opin Pharmacother. 2019 06; 20(8):983-989.
Score: 0.077
-
Microvascular and macrovascular effects of liraglutide. Int J Cardiol. 2019 07 01; 286:17-18.
Score: 0.076
-
Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis. Acta Diabetol. 2019 Mar; 56(3):289-299.
Score: 0.074
-
Pharmacotherapy for gestational diabetes. Expert Opin Pharmacother. 2018 09; 19(13):1407-1414.
Score: 0.074
-
New antihyperglycaemic agents and cardiovascular disease: let's be optimistic. Curr Opin Cardiol. 2018 07; 33(4):444-454.
Score: 0.073
-
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018 09; 1864(9 Pt B):2814-2821.
Score: 0.072
-
Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes. Diabetes Obes Metab. 2017 05; 19(5):613-614.
Score: 0.066
-
Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story. Diabetes Metab Res Rev. 2021 02; 37(2):e3379.
Score: 0.021
-
Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol. 2019 Feb; 12(2):129-143.
Score: 0.019